Cargando…

Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma

Multiple targets RNAi strategy is a preferred way to treat multigenic diseases, especially cancers. In the study, multi-target siRNAs were designed to inhibit NET-1, EMS1 and VEGF genes in hepatocellular carcinoma (HCC) cells. And multi-target siRNAs showed better silencing effects on NET-1, EMS1 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tiejun, Xue, Yuwen, Wang, Guilan, Gu, Tingting, Li, Yunlong, Zhu, York Yuanyuan, Chen, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934040/ https://www.ncbi.nlm.nih.gov/pubmed/27390607 http://dx.doi.org/10.7150/jca.15157

Ejemplares similares

Effects of Triple Effective RNA (teRNA) on the Inhibition of Hepatocellular Carcinoma Cells
por: Xue, Yuwen, et al.
Publicado: (2017)

Therapeutic siRNA: Principles, Challenges, and Strategies
por: Gavrilov, Kseniya, et al.
Publicado: (2012)

Engineering siRNA therapeutics: challenges and strategies
por: Ali Zaidi, Syed Saqib, et al.
Publicado: (2023)

Folate-targeted selenium nanoparticles deliver therapeutic siRNA to improve hepatocellular carcinoma therapy
por: Xia, Yu, et al.
Publicado: (2018)

Therapeutic siRNA: state of the art
por: Hu, Bo, et al.
Publicado: (2020)

Pulmonary delivery of therapeutic siRNA
por: Lam, Jenny Ka-Wing, et al.
Publicado: (2012)

Drug Delivery of siRNA Therapeutics
por: Lamberti, Gaetano, et al.
Publicado: (2020)

Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA
por: Sun, PengMing, et al.
Publicado: (2018)

Potential of siRNA-Bearing Subtilosomes in the Treatment of Diethylnitrosamine-Induced Hepatocellular Carcinoma
por: Jamal, Fauzia, et al.
Publicado: (2023)

siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy
por: Xia, Yu, et al.
Publicado: (2018)

Therapeutic siRNA silencing in inflammatory monocytes
por: Leuschner, Florian, et al.
Publicado: (2011)

Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications
por: Gangopadhyay, Sumit, et al.
Publicado: (2022)

Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma
por: Xia, Yu, et al.
Publicado: (2020)

Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice
por: Bogorad, Roman L, et al.
Publicado: (2014)

Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma
por: Oh, Hea Ry, et al.
Publicado: (2016)

Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy
por: Xia, Yu, et al.
Publicado: (2018)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

Therapeutic reversal of Huntington’s disease by in vivo self-assembled siRNAs
por: Zhang, Li, et al.
Publicado: (2021)

Polyethylene glycol–poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma
por: Wang, Gangmin, et al.
Publicado: (2017)

Preclinical Development of siRNA Therapeutics for AL Amyloidosis
por: Hovey, Beth M., et al.
Publicado: (2011)

Design of siRNA Therapeutics from the Molecular Scale
por: Angart, Phillip, et al.
Publicado: (2013)

Targeted Delivery of siRNA Therapeutics to Malignant Tumors
por: Leng, Qixin, et al.
Publicado: (2017)

Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?
por: Kirkpatrick, D. Lynn, et al.
Publicado: (2012)

Modulation of angiogenesis with siRNA inhibitors for novel therapeutics
por: Lu, Patrick Y., et al.
Publicado: (2005)

siRNA and the lung: research tool or therapeutic drug?
por: de Fougerolles, Antonin, et al.
Publicado: (2008)

siRNA Therapeutics: Future Promise for Neurodegenerative Diseases
por: Amiri, Atefeh, et al.
Publicado: (2021)

Therapeutic siRNA: State-of-the-Art and Future Perspectives
por: Friedrich, Maik, et al.
Publicado: (2022)

The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates
por: Zhang, Lei, et al.
Publicado: (2022)

An Overview of siRNA Delivery Strategies for Urological Cancers
por: Halib, Nadia, et al.
Publicado: (2022)

Engineering a Novel Self-Assembled Multi-siRNA Nanocaged Architecture with Controlled Enzyme-Mediated siRNA Release
por: Moreno, Pedro M. D., et al.
Publicado: (2022)

Silencing of DLGAP5 by siRNA Significantly Inhibits the Proliferation and Invasion of Hepatocellular Carcinoma Cells
por: Liao, Weijia, et al.
Publicado: (2013)

Predicting siRNA efficacy based on multiple selective siRNA representations and their combination at score level
por: He, Fei, et al.
Publicado: (2017)

Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA
por: Yingyuad, Peerada, et al.
Publicado: (2014)

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
por: Berezhnoy, Alexey, et al.
Publicado: (2012)

siRNA Versus miRNA as Therapeutics for Gene Silencing
por: Lam, Jenny K W, et al.
Publicado: (2015)

Dendrimers Show Promise for siRNA and microRNA Therapeutics
por: Dzmitruk, Volha, et al.
Publicado: (2018)

Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics
por: Zare, Mina, et al.
Publicado: (2022)

Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness
por: Farra, Rossella, et al.
Publicado: (2018)

Targeted siRNA Nanoparticles for Mammary Carcinoma Therapy
por: Ben-David-Naim, Meital, et al.
Publicado: (2019)

Where should siRNAs go: applicable organs for siRNA drugs
por: Ahn, Insook, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hbshe238dr23vsoejltt0sv7pq